Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis

There is a significant unmet need for safe and effective anti‐inflammatory treatment for cystic fibrosis. The aim of this study was to evaluate the safety of acebilustat, a leukotriene A4 hydrolase inhibitor, and its effect on inflammation biomarkers in patients with cystic fibrosis. Seventeen patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Elborn, JS, Horsley, A, MacGregor, G, Bilton, D, Grosswald, R, Ahuja, S, Springman, EB
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351012/
https://www.ncbi.nlm.nih.gov/pubmed/27806191
http://dx.doi.org/10.1111/cts.12428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351012/
https://www.ncbi.nlm.nih.gov/pubmed/27806191
http://dx.doi.org/10.1111/cts.12428

Ejemplares similares